VivoSeq
Oncology

Esophageal Carcinoma

50

Pipeline Programs↗

13

Active Trials↗

27

Companies Involved↗

Esophageal Carcinoma is a moderately active landscape with 50 programs across 27 companies. The most active players are Bayer, Betta Pharmaceuticals Co., Ltd., Coherus Oncology, Inc.. 4 therapies are approved with 16 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

61/100

Pipeline Velocity

11/100

Mech. Concentration

18/100

Completion Rate

77/100

Attrition Rate

12/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bayer logo

Bayer

1 program

Phase 1B

Betta Pharmaceuticals Co., Ltd.

1 program

Phase 2C

Coherus Oncology, Inc.

1 program

Phase 2B

Biotech Pharmaceutical Co., Ltd.

1 program

Phase 2I

Imclone

1 program

Phase 2Pfizer logo

Pfizer

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

81%

Small molecule

44 of 54 classified programs — the dominant modality here.

19%ALL OTHERSMonoclonal antibody1019%

Small molecule leads; the ring shows all 54 classified programs, each share of the total. Modality classified for 100% of 55 pipeline programs.

Analysis

Trial Status

49

clinical trials

Completed20 · 41%
Unknown status10 · 20%
Recruiting5 · 10%
Not yet recruiting5 · 10%
Terminated3 · 6%
Withdrawn3 · 6%
Other3 · 6%

Clinical Trials

Trial Activity

49 trials

Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma
Recruiting·HHenan Cancer Hospital·Phase 3·NCT04280822·400 enrolled
JS001 Combined With TP as First-line Treatment for Unresectable or Advanced Small Cell Esophageal Carcinoma
Recruiting·SSun Yat-sen University·Phase 2·NCT05173246·43 enrolled
HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors
Recruiting·HHansoh BioMedical R&D Company·Phase 2·NCT06112704·220 enrolled
Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma
Recruiting·—·Phase 1/2·NCT05937438·70 enrolled
A Comprehensive Preoperative and Postoperative Program Consisting Of Active Physical Therapy, A Comprehensive Nutritional Plan, And Psychological Support For Patients With Locally Advanced, Resectable Cancer Of The Esophagus, Gastroesophageal Junction, and Stomach
Recruiting·MMasaryk Memorial Cancer Institute·Preclinical·NCT07671625·60 enrolled
Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
Active, not recruiting·Merck & Co. logoMerck & Co.·Phase 3·NCT04210115·703 enrolled
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)
Active, not recruiting·Merck & Co. logoMerck & Co.·Phase 3·NCT04949256·864 enrolled
Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.
Active, not recruiting·FFujian Medical University Union Hospital·Phase 1/2·NCT05176002·25 enrolled
Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma
Not yet recruiting·NNanfang Hospital, Southern Medical University·Phase 2·NCT05996484·25 enrolled
Immunotherapy Plus Chemotherapy vs. Chemoradiotherapy for Thoracic Squamous Esophageal Carcinoma
Not yet recruiting·FFujian Medical University Union Hospital·Phase 2·NCT05821452·40 enrolled
Simvastatin Efficacy in ARID1A Mutated Advanced gastroESophageal Carcinoma Treated With Immunotherapy
Not yet recruiting·National Cancer Institute, Naples·Phase 2·NCT07213557·84 enrolled
Efficacy and Safety of QL1706 Plus Lenvatinib As 2nd Line Theapy in Patients with Metastatic Esophageal Carcinoma After Disease Progression on ICIs Therapy
Not yet recruiting·TThe First Affiliated Hospital of Zhengzhou University·Phase 1/2·NCT06746961·49 enrolled
Effect of VExUS Score-Guided Intraoperative Goal-Directed Fluid Therapy on Postoperative Pulmonary Complications in Elderly Patients Undergoing McKeown Minimally Invasive Esophagectomy: A Randomized Controlled Trial
Not yet recruiting·FFirst Affiliated Hospital of Chongqing Medical University·N/A·NCT07691944·126 enrolled
A Study to Evaluate the Combination of Cetuximab and Chemotherapy as Neoadjuvant Therapy Followed Concomitant Chemoradiotherapy Plus Cetuximab in Locoregional Esophageal Carcinoma
Completed·Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)·Phase 2·NCT00733889·50 enrolled
A Study of Participants With Squamous Cell Oesophageal Carcinoma Receiving Nivolumab as Part of an Early Access to Medicines Scheme (EAMS) Program in the United Kingdom
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·N/A·NCT04936399·87 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)